Vevo
Matthew Jones is a highly skilled bioinformatics scientist and postdoctoral scholar currently developing innovative methodologies for studying oncogene amplification and evolution in aggressive cancers at Stanford University. As a founding member of the Vevo Single-Cell Advisory Panel and a key contributor at Vevo Therapeutics, Matthew is involved in advancing in vivo drug discovery using AI models to enhance patient outcomes. With a PhD in Bioinformatics from the University of California, San Francisco, and a B.A. in Computer Science from the University of California, Berkeley, Matthew has significant experience in single-cell lineage tracing, deep learning for disease prediction, and dimensionality reduction for RNA-seq data. Additionally, Matthew has a background in consulting and data representation, having worked with various organizations including Google and Genentech.
This person is not in any offices
Vevo
1 followers
Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.